Folic acid supplementation for 3 wk reduces pulse pressure and large artery stiffness independent of MTHFR genotype

被引:58
作者
Williams, C [1 ]
Kingwell, BA [1 ]
Burke, K [1 ]
McPherson, J [1 ]
Dart, AM [1 ]
机构
[1] Baker Heart Res Inst, Melbourne, Vic 8008, Australia
关键词
homocysteine; genetics; MTHFR gene; folate therapy; arterial stiffness; pulse pressure; hypertension;
D O I
10.1093/ajcn/82.1.26
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Folic acid reduces plasma homocysteine and may be an important therapy for preventing cardiovascular disease. A key mechanism may be the reduction of arterial stiffness. Objective: The effect of folic acid supplementation on blood pressure and large artery stiffness was examined in relation to methylenetetrahydrofolate reductase (MTHFR) genotype. Design: Forty-one asymptomatic men with normal or high-normal ambulatory blood pressure (systolic: > 130 to < 145 mm Hg; diastolic: > 80 to < 90 mm Hg) participated. The study had a randomized, placebo-controlled, double-blind, crossover design that incorporated 3-wk treatments with 5 mg folic acid/d or matching placebo; each treatment was separated by a 4-wk washout phase. Results: Folic acid reduced brachial pulse pressure by 4.7 +/- 1.6 mm Hg (P < 0.05) without changing mean arterial pressure. Systemic arterial compliance increased by 0.15 +/- 0.03 mL/mm Hg (P < 0.05) after folic acid treatment but did not change after placebo treatment. These responses did not significantly correlate with either homocysteine or folate plasma concentrations. MTHFR genotype CC homozygotes (without the 677C -> T polymorphism) with normal blood pressure had a larger reduction in homocysteine concentrations in response to folic acid than did T allele carriers. Blood pressure and arterial stiffness responses were independent of MTHFR genotype. Conclusion: Folic acid is a safe and effective supplement that targets large artery stiffness and may prevent isolated systolic hypertension.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 57 条
[1]   Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease [J].
Anderson, JL ;
Muhlestein, JB ;
Horne, BD ;
Carlquist, JF ;
Bair, TL ;
Madsen, TE ;
Pearson, RR .
CIRCULATION, 2000, 102 (11) :1227-1232
[2]   Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement:: a randomized controlled trial [J].
Ashfield-Watt, PAL ;
Pullin, CH ;
Whitting, JM ;
Clark, ZE ;
Moat, SJ ;
Newcombe, RG ;
Burr, ML ;
Lewis, MJ ;
Powers, HJ ;
McDowell, IFW .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 76 (01) :180-186
[3]   Pulse pressure -: A predictor of long-term cardiovascular mortality in a French male population [J].
Benetos, A ;
Safar, M ;
Rudnichi, A ;
Smulyan, H ;
Richard, JL ;
Ducimetière, P ;
Guize, L .
HYPERTENSION, 1997, 30 (06) :1410-1415
[4]   Influence of homocysteine on matrix metalloproteinase-2:: Activation and activity [J].
Bescond, A ;
Augier, T ;
Chareyre, C ;
Garçon, D ;
Hornebeck, W ;
Charpiot, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 263 (02) :498-503
[5]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057
[6]   Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients - A longitudinal study [J].
Boutouyrie, P ;
Tropeano, AI ;
Asmar, R ;
Gautier, I ;
Benetos, A ;
Lacolley, P ;
Laurent, S .
HYPERTENSION, 2002, 39 (01) :10-15
[7]  
Brattström L, 2000, AM J CLIN NUTR, V72, P315
[8]  
Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
[9]  
Bryan J, 2004, J Nutr Health Aging, V8, P226